Pulse Explorar nav.journalClub Debates Tendencias Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors | Synapse

October 25, 2019Open Access

Ver artículo completo

177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors

SDSatya DasTherapeutics Clinical Research TATaymeyah Al‐ToubahMoffitt Cancer Center GEGhassan El‐HaddadMoffitt Cancer Center

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Lu-DOTATATE fits into the treatment sequence for GEP NET patients remains an area of active investigation.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Das et al. (Fri,) studied this question.

synapsesocial.com/papers/69ff4913831589f3542d816b https://doi.org/https://doi.org/10.1080/17474124.2019.1685381

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors.2018 · 28 citations
2First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas2010 · 766 citations
3Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study2014 · 263 citations
4Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms2019 · 67 citations
5Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States2017 · 3,487 citations